GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Price-to-Tangible-Book

Entera Bio (FRA:5DT) Price-to-Tangible-Book : 9.04 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Price-to-Tangible-Book?

As of today (2024-05-22), Entera Bio's share price is €2.08. Entera Bio's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was €0.23. Hence, Entera Bio's Price to Tangible Book Ratio of today is 9.04.

The historical rank and industry rank for Entera Bio's Price-to-Tangible-Book or its related term are showing as below:

FRA:5DT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.79   Med: 3.99   Max: 12.92
Current: 8.67

During the past 9 years, Entera Bio's highest Price to Tangible Book Ratio was 12.92. The lowest was 1.79. And the median was 3.99.

FRA:5DT's Price-to-Tangible-Book is ranked worse than
86.02% of 1223 companies
in the Biotechnology industry
Industry Median: 2.85 vs FRA:5DT: 8.67

A closely related ratio is called PB Ratio. As of today, Entera Bio's share price is €2.08. Entera Bio's Book Value per Sharefor the quarter that ended in Mar. 2024 was €0.23. Hence, Entera Bio's P/B Ratio of today is 9.04.


Entera Bio Price-to-Tangible-Book Historical Data

The historical data trend for Entera Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Price-to-Tangible-Book Chart

Entera Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only - 2.80 3.69 1.57 1.78

Entera Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.30 2.77 3.25 1.78 6.09

Competitive Comparison of Entera Bio's Price-to-Tangible-Book

For the Biotechnology subindustry, Entera Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Entera Bio's Price-to-Tangible-Book falls into.



Entera Bio Price-to-Tangible-Book Calculation

Entera Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=2.08/0.23
=9.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Entera Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Entera Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio (FRA:5DT) Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines